Merck & Co Inc
NYSE: MRK
$117.00
-$0.23 (-0.2%)
Real Time Data Delayed 15 Min.
MRK Articles
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
The 2021 Dogs of the Dow are now known, and investors who may want to follow this investing strategy have got some thinking to do.
Published:
Six Dow stocks are on track to lose at least 10% of their value in 2020. Here's a look at what's happened.
Published:
One popular investment strategy, known as the Dogs of the Dow, has performed better than last year. What's ahead for the dogs in 2021?
Published:
Last Updated:
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
Published:
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Published:
Merck has joined the fight against COVID-19 by acquiring OncoIummune in an all-cash transaction.
Published:
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Published:
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
Published:
Roughly a third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Published:
Health care is one sector that continues to draw a ton of fund manager interest, and with good reason. These five dividend-paying health care stocks are all favored by large-cap portfolio managers.
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
Published:
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
Published:
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Published:
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Published: